Brain tumors cancer of blood cells tumors of the central nervous system
Conditions
Interventions
None listed
Sponsors
Prinses Máxima Centrum voor Kinderoncologie
Eligibility
Age
No minimum to 64 Years
Inclusion criteria
Inclusion criteria: For Brain tumor arm: In order to be eligible to participate in this study, a subject must meet all of the following criteria: Patients - Age 0 - 25 years at inclusion - Newly diagnosed brain tumor or relapse of a brain tumor including craniopharyngiomas - MRI representing an image of a brain tumor, not resembling a germcell tumor - Clinical indication for tumor biopsy/resection - Written (parental) informed consent Healthy controls - Sibling of a patient already participating in the MIMIC brain study - Age 0 - 25 years at inclusion - Written (parental) informed consent For AML: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Age 0 - 21 years at inclusion - Treatment at a Pediatric Cancer Center - Newly diagnosed AML or relapse of AML - Written (parental) informed consent
Exclusion criteria
Exclusion criteria: For Brain tumor arm: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Suspected germ cell tumor on radiology or based on tumor markers (aFP, βHCG) For AML arm: A potential subject who meets any of the following criteria will be excluded from participation in this study: - acute myeloid leukemia in children with Down syndrome - acute promyelocytic leukemia (APL)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Brain tumors: To characterize and quantify changes in immune parameters during disease within patients with a CNS malignancy AML: To characterize and quantify changes in immune parameters during disease within patients with AML. | — |
Secondary
| Measure | Time frame |
|---|---|
| Brain tumors: Secondary Objectives To evaluate the effect of therapy on the immune profiles To evaluate survival for different molecular- and immune profiles Explorative Objectives To determine tumor-specific cell surface proteins To characterize tumor infiltrating lymphocytes To determine faeces composition To correlate molecular characteristics with the immune profile for the different tumor entities AML: Exploratory objectives: To evaluate survival and treatment response for different molecular- and immune profiles To characterize the amenability of primary AML samples and immune cells to respond to immunotherapy in preclinical models | — |
Countries
Netherlands
Contacts
Public ContactJ. Lugt
Prinses Máxima Centrum voor Kinderoncologie
Outcome results
None listed